Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Researchers pooled data from phase 3 BRUIN CLL-313 and BRUIN CLL-314 clinical trials to assess efficacy and safety of pirtobrutinib in treatment-naive patients with chronic lymphocytic leukemia /small ...

Discussions Around the DeLLphi-305 Trial / Amgen, Antonio Calles, AstraZeneca, cancer, DeLLphi-305, Durvalumab, ESMO, Estela ...

Dakota Gold Corp. (NYSE American: DC) ("Dakota Gold" or the "Company") is pleased to provide results from the Pre-Feasibility Study ("PFS") metallurgical test program for its Richmond Hill Oxide Heap ...

September 10, 2026) - Cabral Gold Inc.  (TSXV: CBR) (OTCQX: CBGZF) ("Cabral" or the "Company") is pleased to announce the ...

Analysts propose that this positive readout in ES-SCLC could see Imdelltra move into the frontline setting within this indication.

Ku, MD, highlights emerging therapies in the treatment paradigm for patients with gastric and gastroesophageal junction cancers. In a recent interview with Targeted Oncology, Geoffrey Y. Ku, MD, ...

Elevra’s Chief Executive Officer and Managing Director, Mr Lucas Dow, said: “The NAL Expansion PFS confirms a compelling value proposition for Elevra, with a high-return brownfield expansion that ...

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...

Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival (PFS) demonstrated by its OX40 agonist ...

Australia-based developer Brazilian Rare Earths (BRE) has produced its first rare earth concentrate at its stage one pilot facility in Camacari, located in Brazil's northeastern Bahia state.

Akeso and Summit Therapeutics' ivonescimab has shown further benefit in a first-line non-small cell lung cancer (NSCLC) Phase III study, meeting the key secondary overall survival (OS) endpoint.